-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

When Should We Use It? The Role of Brentuximab Vedotin in 2024

Program: Education Program
Session: Moving the Needle in Hodgkin Lymphoma
Saturday, December 7, 2024, 9:30 AM-10:45 AM

Ranjana H. Advani, MD

Department of Medicine, Division of Oncology and Hematology, Stanford University, Stanford, CA; Stanford University, Stanford, CA

Disclosures: Advani: Autolus: Honoraria, Other: DSMB/Advisory Boards; Gilead: Research Funding; Regeneron: Research Funding; Cyteir: Research Funding; Seattle Genetics: Research Funding; ADCT: Honoraria, Other: DSMB/Advisory Boards; BeiGene: Honoraria, Other: DSMB/Advisory Boards, Research Funding; Roche/Genentech: Honoraria, Other: Steering committee, DSMB/Advisory Boards, Research Funding; Merck: Other: Steering committee, DSMB/Advisory Boards, Research Funding.

OffLabel Disclosure:

See more of: Moving the Needle in Hodgkin Lymphoma
See more of: Education Program
<< Previous Presentation | Next Presentation >>